Lung cancer is having a malignant tumor in the lungs especially in the cells lining air passages.
Primary tumor-related signs and symptoms are cough, dyspnea, hemoptysis, and chest discomfort.
Signs and symptoms due to intrathoracic spread may involve the nerves (hoarseness, dyspnea, muscle wasting of upper limb, Horner's syndrome), chest wall and pleura (chest pain, dyspnea) and vascular structures (facial swelling, dilated neck veins, cardiac tamponade) & viscera (dsyphagia).
The signs and symptoms due to metastatic spread are bone pain with or without pleuritic pain, neurologic symptoms, limb weakness, unsteady gait, cervical lymphadenopathy, and skin nodules.
Patients with non–small-cell lung cancer (NSCLC) who underwent radiotherapy had a high risk for major adverse cardiac events (MACE) within 2 years post-therapy, with the cardiac radiation dose exposure being an independent predictor of MACE and all-cause mortality, a large retrospective study shows.
Use inhaled corticosteroids (ICSs) in patients with chronic obstructive pulmonary disease (COPD) was associated with a significantly reduced risk of developing lung cancer compared with patients without ICS exposure, according to data from the CORE* study.
Patients with previously-treated non-small-cell lung cancer (NSCLC) who responded early to nivolumab at 6 months showed better long-term survival compared with responders to docetaxel, according to pooled analyses of CheckMate 017 and CheckMate 057 presented at the AACR 2019 Annual Meeting.
Patients with advanced small cell lung cancer (SCLC) who experience disease progression despite two or more lines of therapy could benefit from pembrolizumab in the third-line setting, according to results from the phase 1b KEYNOTE-028 and phase II KEYNOTE-158* studies presented at AACR 2019.
Patients with EGFR-positive non-squamous non-small-cell lung cancer (NSCLC) had greater progression-free survival (PFS) when treated with erlotinib plus bevacizumab rather than erlotinib alone, according to an interim analysis of the phase III NEJ026 trial.
Patients with extensive stage small cell lung cancer (ES-SCLC) without brain metastasis who underwent prophylactic cranial irradiation (PCI) after achieving stable disease or better on first-line chemotherapy had improved overall survival (OS) compared with those who did not undergo PCI, according to a retrospective study from Singapore.
Patients with advanced non-small-cell lung cancer (NSCLC) and brain metastases demonstrated better progression-free survival (PFS) when initiating the oral EGFR* TKI** afatinib at a higher rather than a lower dose, according to a retrospective study from Singapore.
Cough is a common and distressing symptom with an unmet clinical need in lung cancer patients, a study reports. This symptom is associated with gastrointestinal symptoms but not with smoking, cancer stage, location, treatment and chronic obstructive pulmonary disorder.